VOYAGER THERAPEUTICS INC
VYGRNASDAQTrading Snapshot
- Day Range
- $2.62 – $2.68
- 52-Week Range
- $2.58 – $5.55
- Volume
- $2.65B
- Avg Volume
- $2.15B
- Shares Outstanding
- 60.4M
- Next Earnings
- Nov 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $40M
- Last Q Revenue
- $3M
- P/E Ratio
- -1.5
- P/S Ratio
- 4.6x
- EPS (TTM)
- $-1.78
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +1.2%
Why Investors Own VYGR
- ✓High-growth profile — revenue up +45.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 66% gross margin and 5% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
VOYAGER THERAPEUTICS INC
VYGR
StockOtter · stockotter.spaceAbout VOYAGER THERAPEUTICS INC
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Tonix Pharmaceuticals (NASDAQ:TNXP) and Voyager Therapeutics (NASDAQ:VYGR) Critical Review
Tonix Pharmaceuticals (NASDAQ: TNXP - Get Free Report) and Voyager Therapeutics (NASDAQ: VYGR - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two busin
Aligos Therapeutics (NASDAQ:ALGS) & Voyager Therapeutics (NASDAQ:VYGR) Head-To-Head Analysis
Aligos Therapeutics (NASDAQ: ALGS - Get Free Report) and Voyager Therapeutics (NASDAQ: VYGR - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two busines
Voyager Therapeutics, Inc. (VYGR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Voyager Therapeutics, Inc. (VYGR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
BlackRock Inc. Takes $18.10 Million Position in Voyager Therapeutics, Inc. $VYGR
BlackRock Inc. acquired a new position in shares of Voyager Therapeutics, Inc. (NASDAQ: VYGR) in the undefined quarter, according to its most recent disclosure with the SEC. The fund acquired 5,172,063 shares of the comp
Voyager to Present at Upcoming Investor Conferences
LEXINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company wi
Dimensional Fund Advisors LP Sells 208,931 Shares of Voyager Therapeutics, Inc. $VYGR
Dimensional Fund Advisors LP decreased its position in Voyager Therapeutics, Inc. (NASDAQ: VYGR) by 19.3% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 875,